APA (7th ed.) Citation

Chanchlani, N., Lin, S., Chee, D., Hamilton, B., Nice, R., Arkir, Z., . . . McDonald, T. J. (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's & Colitis, 16(3), 389. https://doi.org/10.1093/ecco-jcc/jjab153

Chicago Style (17th ed.) Citation

Chanchlani, Neil, et al. "Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients." Journal of Crohn's & Colitis 16, no. 3 (2022): 389. https://doi.org/10.1093/ecco-jcc/jjab153.

MLA (9th ed.) Citation

Chanchlani, Neil, et al. "Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients." Journal of Crohn's & Colitis, vol. 16, no. 3, 2022, p. 389, https://doi.org/10.1093/ecco-jcc/jjab153.